Atlanta – – September 18, 2026 -- Alzamend Neuro, Inc. (Nasdaq: ALZN) has regained compliance with Nasdaq's minimum stockholders' equity rule, ending a listing threat that began in March 2026.
Nasdaq confirms Alzamend's equity now exceeds required threshold
Nasdaq's Listing Qualifications Staff issued a notification letter dated September 14, 2026, confirming Alzamend satisfies Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2.5 million. Alzamend's Quarterly Report on Form 10-Q for the quarter ended July 31, 2026, filed with the SEC on September 10, 2026, showed stockholders' equity of $5,802,680, more than double the required minimum.
Company faced a six-month compliance clock after March delisting warning
Nasdaq first flagged Alzamend on March 20, 2026, for failing to meet minimum market value and equity requirements for continued listing. The company was given 45 calendar days, until May 4, 2026, to submit a remediation plan; Nasdaq accepted the plan and extended the deadline to September 16, 2026, which Alzamend has now met.
CEO shifts focus to four-arm Phase II program with Massachusetts General Hospital
CEO Stephan Jackman said the company's "full focus returns to advancing AL001 through four Phase II clinical trials in partnership with Massachusetts General Hospital." The healthy human cohort for AL001 launched in May 2025, completed its clinical portion in November 2025, and yielded topline data in March 2026. Alzamend initiated the bipolar disorder cohort in April 2026 and plans to sequentially launch the remaining cohorts in Alzheimer's disease, major depressive disorder and post-traumatic stress disorder patients.